Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01501084 · ClinicalTrials.gov registry record · Phase 1
Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01501084 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 34 participants.
The verdict
NCT01501084, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
Obesity is a major health problem in the US and many Western countries, with more than half of the population being overweight or obese. Yet, despite intense research efforts into the mechanisms underlying obesity and into the development of novel pharmacologic interventions, bariatric surgery, including gastric bypass surgery is the only successful treatment for severe obesity. Mimicking one of the effects of bariatric surgery, e.g. the increased secretion of glucagon-like peptide 1 (GLP-1) could be an effective strategy against obesity. Obese individuals may be more sensitive to the rewarding aspects of food and less responsive to signals from the gut about actual energy needs. Using functional MRI scanning the investigators plan to examine the effect of Exenatide (a GLP-1 analog known to reduce caloric intake and produce weight loss in both obese and lean individuals) on activity within brain regions/networks involved in reward/motivation and in regulation of energy requirements. The investigators expect the peptide to change the balance between desire to eat for pleasure and the need to eat to maintain homeostasis.
Interventions
- DRUG Exenatide
- DRUG Normal saline .2cc subcutaneous injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01501084
The ClinicalTrials.gov registry entry for NCT01501084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exenatide is the first listed.
NCT01501084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01501084 about?
NCT01501084 is a clinical study titled "Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women". Obesity is a major health problem in the US and many Western countries, with more than half of the population being overweight or obese. Yet, despite intense research efforts into the mechanisms underlying obesity and into the development of novel pharmacologic interventions, bariatric surgery, incl...
What is the current status of trial NCT01501084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2011-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01501084?
The interventions under investigation include: Exenatide (DRUG), Normal saline .2cc subcutaneous injection (DRUG).
Who is sponsoring clinical trial NCT01501084?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.